• Products
    • Quality Controls & Reference Standards
      • gDNA
      • cfDNA / ctDNA
      • Plasma (human-tech) DNA free
      • Plasma (human-tech) + cfDNA / ctDNA
      • FFPE
  • Service
    • COVID-19 Diagnosis
  • News
  • Company
    • About us
    • Quality Management
    • Roadmap
    • Job and career
  • Support
    • Contact us
    • Documents & Certificates
    • Payment and Shipping
  • English
    • German
  • Products
    • Quality Controls & Reference Standards
      • gDNA
      • cfDNA / ctDNA
      • Plasma (human-tech) DNA free
      • Plasma (human-tech) + cfDNA / ctDNA
      • FFPE
  • Service
    • COVID-19 Diagnosis
  • News
  • Company
    • About us
    • Quality Management
    • Roadmap
    • Job and career
  • Support
    • Contact us
    • Documents & Certificates
    • Payment and Shipping
  • English
    • German

SensID GmbH

SensID GmbH

  • Products
    • Quality Controls & Reference Standards
      • gDNA
      • cfDNA / ctDNA
      • Plasma (human-tech) DNA free
      • Plasma (human-tech) + cfDNA / ctDNA
      • FFPE
  • Service
    • COVID-19 Diagnosis
  • News
  • Company
    • About us
    • Quality Management
    • Roadmap
    • Job and career
  • Support
    • Contact us
    • Documents & Certificates
    • Payment and Shipping
  • English
    • German

2016

12. November 2018
2016eesslinger2018-11-12T10:51:39+01:00

Development of the business model and investors acquisition.

Post navigation

← 2018
2015 →

SensID GmbH
Schillingallee 68
D-18057 Rostock
Germany
Phone +49 (0) 381 377 182 01
info@sens-id.com

LinkedIn
YouTube

Site Links

  • Imprint
  • Data Protection
  • Terms and Conditions

Products

  • gDNA
  • cfDNA / ctDNA
  • Plasma (human-tech) DNA free
  • Plasma (human-tech) + cfDNA / ctDNA







© SensID GmbH

We use cookies to ensure we give you the best experience on our website. We use cookies to help remember your log-in details and optimise the site functionality for your use.OKData protection